#United States #Bethesda #ASHP #Prescription Drugs #Weight-Loss Medications

Rise in U.S. Prescription Drug Spending

As the demand for weight-loss medications continues to surge, prescription drug spending in the United States is projected to cross the $1 trillion mark in 2026. This substantial increase is rooted in the soaring costs associated with popular drugs such as tirzepatide and semaglutide, both of which accounted for roughly $60 billion each in spending in 2025, a stark increase compared to the $29 billion spent on apixaban, a commonly prescribed blood thinner.

According to the annual drug expenditures report by the American Society of Health-System Pharmacists (ASHP), the total spending on prescription drugs surged by 12.7% in 2025, reaching approximately $915 billion. This growth rate marks one of the fastest increases in the last two decades, significantly outpacing the general healthcare and overall economic growth in the U.S.

The Impact of GLP-1 Drugs

A significant contributing factor to this growth is the introduction of GLP-1 receptor agonists, which have been dubbed as game-changers in the prescription drug landscape. Eric Tichy, PharmD, MBA, and lead author of the ASHP report, stated that GLP-1 medications alone accounted for nearly one-third of all spending growth, amplifying the overall market dynamics.

Interestingly, GLP-1 drugs comprise about 14% of total prescription drug spending in the U.S., excluding direct-to-consumer sales. This suggests that their overall market impact is even broader than initially estimated.

A Diverse Patient Population Drives Spending

The report also emphasizes that the anticipated spike in drug spending is largely linked to the increasing number of patients utilizing various medications rather than just rising drug prices. Forecasts indicate a spending growth of 10–12% overall, with clinics experiencing the highest rise at 14–16%, and hospitals seeing a 4–6% increase.

Tichy notes that for many healthcare systems, escalating drug expenditures represent more than just another cost; these new therapies have become integral components in providing effective patient care. The challenge lies in ensuring that all patients can access these vital treatments, irrespective of their geographic location or employment status.

Highlights from 2025 Drug Expenditure Trends

The report outlines several key trends observed in 2025:

• - Cancer Drugs: The largest and fastest-growing segment within hospitals and clinics, with spending increasingly focused on precision oncology, immune checkpoint inhibitors, and antibody-drug conjugates.
• - Biosimilars: Notable upwards trends in biosimilar usage, especially in fields like oncology and immunology, offer potential for cost savings while varying by drug and site of care.
• - Specialty Drugs: Clinics reported an impressive growth rate of 19%, bolstered by the advent of specialty and injectable drugs, particularly in oncology and rare diseases.

The report warns, however, that drug expenditure growth may not be uniform across the country. Organizations focusing on oncology, specialty medicine, and rare diseases are expected to face much steeper increases compared to those that provide routine care. This variance highlights the necessity for localized data analysis to guide future planning.

Looking Ahead: Federal Policies and Access

Future federal policy changes are anticipated to significantly impact both medication access and usage. Initiatives like Medicare drug-price negotiations and Part D benefit redesign are projected to lessen out-of-pocket expenses for patients, potentially leading to higher medication utilization rates.

In such a rapidly evolving environment of prescription drug expenditures, having data-driven projections becomes paramount for healthcare decision-makers. Daniel J. Cobaugh, PharmD, emphasized the importance of the ASHP report as a key benchmark for stakeholders in pharmacy and healthcare.

In conclusion, the increasing trajectory of U.S. prescription drug spending signals both challenges and opportunities for health systems. As medication use continues to grow, ensuring equitable access to these treatments will be vital in shaping future healthcare landscapes.